Market closed
Indaptus Therapeutics/$INDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Indaptus Therapeutics
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Ticker
$INDP
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
7
Website
INDP Metrics
BasicAdvanced
$7.4M
-
-$1.61
1.11
-
Price and volume
Market cap
$7.4M
Beta
1.11
52-week high
$1.70
52-week low
$0.43
Average daily volume
836K
Financial strength
Current ratio
1.95
Quick ratio
1.705
Total debt to equity
2.134
Management effectiveness
Return on assets (TTM)
-86.28%
Return on equity (TTM)
-187.52%
Valuation
Price to book
1.55
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-0.387
Growth
Earnings per share change (TTM)
-12.54%
3-year earnings per share growth (CAGR)
-5.21%
INDP News
AllArticlesVideos
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
GlobeNewsWire·3 weeks ago
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
GlobeNewsWire·4 weeks ago
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Indaptus Therapeutics stock?
Indaptus Therapeutics (INDP) has a market cap of $7.4M as of April 16, 2025.
What is the P/E ratio for Indaptus Therapeutics stock?
The price to earnings (P/E) ratio for Indaptus Therapeutics (INDP) stock is 0 as of April 16, 2025.
Does Indaptus Therapeutics stock pay dividends?
No, Indaptus Therapeutics (INDP) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Indaptus Therapeutics dividend payment date?
Indaptus Therapeutics (INDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Indaptus Therapeutics?
Indaptus Therapeutics (INDP) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.